| pubmed-article:15366970 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C0006118 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C1292734 | lld:lifeskim |
| pubmed-article:15366970 | lifeskim:mentions | umls-concept:C0301869 | lld:lifeskim |
| pubmed-article:15366970 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15366970 | pubmed:dateCreated | 2004-9-15 | lld:pubmed |
| pubmed-article:15366970 | pubmed:abstractText | T cell immunotherapy is a potential strategy for the treatment of brain tumors because it offers a high degree of specificity, the ability to extravasate into solid tumors, and the potential for eliciting a long-term protective immune response. Various approaches have been developed to overcome T cell immune tolerance to cancer, including the use of cytokines and bispecific antibodies. T cell stimulation with the proinflammatory cytokine IL-12 can elicit antitumor immunity. T cell activation can be increased using bispecific antibodies against activating molecules on the surface of T cells and a tumor antigen. We studied the effects of systemic IL-12 administration in combination with a conjugate of an anti-CD28 antibody and a ligand for the folate receptor. The high affinity folate receptor is expressed on endogenously arising choroid plexus tumors of SV11 mice, which are transgenic for large T antigen under the control of the SV40 promoter. SV11 mice are immunocompetent, yet immunologically tolerant to large T antigen expressed by choroid plexus tumors. MRI analysis showed that the administration of IL-12 and anti-CD28 Fab/folate significantly slowed tumor growth. Proliferating CD8(+) T cells were found in choroid plexus tumors of treated animals. Treatment of animals with IL-12 + anti-CD28 Fab/folate prolonged survival compared to IL-12 alone. Cytokine treatment combined with tumor-targeted costimulation may be a useful adjunct treatment. | lld:pubmed |
| pubmed-article:15366970 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15366970 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15366970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15366970 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15366970 | pubmed:issn | 1043-1802 | lld:pubmed |
| pubmed-article:15366970 | pubmed:author | pubmed-author:KranzDavid... | lld:pubmed |
| pubmed-article:15366970 | pubmed:author | pubmed-author:RoyEdward JEJ | lld:pubmed |
| pubmed-article:15366970 | pubmed:author | pubmed-author:GawlickUteU | lld:pubmed |
| pubmed-article:15366970 | pubmed:author | pubmed-author:SchepkinVicto... | lld:pubmed |
| pubmed-article:15366970 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15366970 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:15366970 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15366970 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15366970 | pubmed:pagination | 1137-45 | lld:pubmed |
| pubmed-article:15366970 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:meshHeading | pubmed-meshheading:15366970... | lld:pubmed |
| pubmed-article:15366970 | pubmed:articleTitle | A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. | lld:pubmed |
| pubmed-article:15366970 | pubmed:affiliation | Neuroscience Program and Department of Biochemistry, University of Illinois, Urbana, Illinois 61801, USA. | lld:pubmed |
| pubmed-article:15366970 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15366970 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15366970 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15366970 | lld:pubmed |
